Judul: Kajian Formulasi Lighter Biscuit Dalam Rangka Pengembangan Produk Baru Di PT Arnott’s Indonesia Bekasi
Abstrak: Pengembangan produk baru adalah suatu usaha ekstensifikasi dari suatu perusahaan pangan yang merupakan hasil kerja sama antara bagian pengembangan produk, pemasaran, produksi, pengawasan mutu, dan bagian persediaan bahan. Penelitian dan pengembangan merupakan kegiatan perusahaan dalam rangka mengembangkan produk baru dan mengantisipasi perubahan pasar. Formulasi produk merupakan bagian dalam tahap pengembangan produk. Tahap ini merupakan tahap yang sangat penting dalam penciptaan produk baru. Pada tahap ini dicari beberapa alternatif formulasi bahan baku produk sampai dihasilkan formulasi yang optimum hingga dihasilkan produk bermutu yang secara ekonomis menguntungkan dan secara organoleptik dapat diterima dan disukai oleh konsumen.
Keyword: 

Judul: Pengembangan informasi nilai gizi pangan produk biskuit, cookies, wafer, dan wafer stick untuk tujuan klaim produk di PT. Arnotts Indonesia
Abstrak: Nutritional fact in food products has enormous importance for customers. The development of nutritional fact and any claims of the food products must follow certain regulations from Indonesian Authorities. Case study to develop nutritional fact and potential claims for biscuit, cookies, wafer and wafer stick products in PT. Arnotts Indonesia includes analysis and verification of nutrition content in the products and calculation which align with last updated regulations from BPOM and Indonesian Health Ministry. Accurate proximate analysis from representative samples for nutrition content holds significant importance in the reliability of the nutritional fact and claim developed. The nutrition fact and claims of the product then can be written down in the packaging by following the Food Labeling guidelines.
Keyword: 

Judul: Pemurnian dan karakterisasi protein inhibitor RNA helikase virus hepatitis C
Abstrak: Hepatitis C virus (HCV) infection is the second most common chronic viral infection in the world with global prevalence. This infection is contribution to chronic hepatitis and liver cirrhosis, often leading to hepatocellular carcinoma. There is no effective drug and vaccine available against HCV. The current standard treatment, a combination of pegylated interferon-α with ribavirin, is limited by its suboptimal response rate in a significant patient population, side effects, and affordability. Therefore, development of effective drug is needed. One approach to find out the candidate of antiviral drug is to discover the inhibitor of enzyme that essential for virus replication, such as RNA helicase. Streptomyces chartreusis 5-095 produce the inhibitor of HCV RNA helicase. The aim of this study was to purify the protein inhibitor which has inhibition activity against ATPase activity of RNA helicase HCV from S. chartreusis 5-095. The supernatant of culture S. chartreusis 5-095 exhibited high inhibiton activity against ATPase activity of RNA helicase HCV (approximately 72%) at 10 days of incubation. The extracellular protein inhibitor was partially purified by procedures of precipitation with ammonium sulfate to 65% saturation and gel filtration (Sephadex G50) using methanol water solution (4:6) as an eluen. The purity of protein inhibitor was monitored by SDS PAGE. The protein inhibitor showed a relative molecular mass were estimated to be 14 kDa and increased the purity 23,08 fold than those of the crude protein. The specific activity and IC50 after purification were 13,1338 U/mg and 0,0767 mg/mL, respectively. The activity of purified protein inhibitor showed its stability over pH range from 5-8 and optimum at pH 7,4. The inhibition activity showed its stability up to 70% at temperature 100 oC. The purified protein inhibitor relatively stable its activity at storage in the range of -20 oC to room temperature for 35 days.
Keyword: